非基因成同步小细胞肺癌的当前争议和挑战:一篇综述
Mandy Jongbloed1, Martina Bortolot2, Jonas Willmann3,4
1Department of Pulmonary Diseases, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.
JAMA oncology
|September 4, 2025
概括
在接受维持免疫治疗的同步小细胞非肺癌 (NSCLC) 患者中,局部激素治疗 (LRT) 没有改善生存率. 一个真正的寡头成形状态的存在仍然不确定.
科学领域:
- 癌症学
- 医学成像
- 基因组学
背景情况:
- 在成像和治疗方面取得的进展表明,治疗同期寡头转移性疾病 (sOMD) 的潜在好处.
- 在NRG- LU002试验中,研究了在小细胞肺癌 (NSCLC) 中增加局部激素治疗 (LRT) 维持系统治疗.
研究的目的:
- 讨论治疗非癌基因成性SOMD的挑战和争议.
- 评估LRT在当代免疫疗法中的作用,并探索真正的sOMD状态的存在.
主要方法:
- 审查目前的文献和临床试验数据,包括NRG-LU002试验.
- 讨论影响转移潜力的生物因素以及区分sOMD与广泛疾病的成像限制.
主要成果:
- 在NRG-LU002试验中,没有发现LRT与小细胞瘤性NSCLC的维持系统治疗相加的无进展或整体存活率有显著改善.
- 目前的成像方法无法可靠地区分真正的sOMD和早期广泛的转移性疾病,这使得患者选择激进的策略变得复杂.
结论:
- 作为一个独特的生物实体,同步寡头转移性NSCLC的存在受到争议.
- 生物标志物如ctDNA,microRNA和放射学需要进一步验证以改善临床试验中的患者选择,强调转化研究的必要性.
更多相关视频
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.2K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
